182 related articles for article (PubMed ID: 26396498)
1. Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics.
Kim JR; Woo HI; Chun MR; Lim SW; Kim HD; Na HS; Chung MW; Myung W; Lee SY; Kim DK
Drug Des Devel Ther; 2015; 9():5247-54. PubMed ID: 26396498
[TBL] [Abstract][Full Text] [Related]
2. Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects
.
Chen R; Shen K; Hu P
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):231-236. PubMed ID: 27936523
[TBL] [Abstract][Full Text] [Related]
3. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.
Yasui-Furukori N; Saito M; Inoue Y; Niioka T; Sato Y; Tsuchimine S; Kaneko S
Eur J Clin Pharmacol; 2007 Jan; 63(1):51-6. PubMed ID: 17124578
[TBL] [Abstract][Full Text] [Related]
4. Nonadherence to paroxetine: a study based on monitoring plasma paroxetine levels.
Yoshimura R; Ikenouchi-Sugita A; Umene-Nakano W; Hori H; Ueda N; Nakamura J
J Clin Psychopharmacol; 2010 Feb; 30(1):82-3. PubMed ID: 20075657
[No Abstract] [Full Text] [Related]
5. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder.
Findling RL; Nucci G; Piergies AA; Gomeni R; Bartolic EI; Fong R; Carpenter DJ; Leeder JS; Gaedigk A; Danoff TM
Neuropsychopharmacology; 2006 Jun; 31(6):1274-85. PubMed ID: 16319918
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD
J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
[TBL] [Abstract][Full Text] [Related]
7. Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
Nishimura M; Ueda M; Saruwatari J; Nakashima H; Ogusu N; Aoki A; Tsuchimine S; Matsuda K; Iwashita K; Ono T; Oniki K; Shimoda K; Yasui-Furukori N
Pharmacogenet Genomics; 2016 Sep; 26(9):403-13. PubMed ID: 27187662
[TBL] [Abstract][Full Text] [Related]
8. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment.
Zourková A; Hadasová E
J Sex Marital Ther; 2002; 28(5):451-61. PubMed ID: 12378847
[TBL] [Abstract][Full Text] [Related]
9. The serotonin syndrome scale: first results on validity.
Hegerl U; Bottlender R; Gallinat J; Kuss HJ; Ackenheil M; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 1998; 248(2):96-103. PubMed ID: 9684919
[TBL] [Abstract][Full Text] [Related]
10. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy.
Ruhé HG; Booij J; v Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene AH
Neuropsychopharmacology; 2009 Mar; 34(4):999-1010. PubMed ID: 18830236
[TBL] [Abstract][Full Text] [Related]
11. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
Chen R; Wang H; Shi J; Shen K; Hu P
Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
[TBL] [Abstract][Full Text] [Related]
13. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
Miner CM; Brown EB; Gonzales JS; Munir R
J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
[TBL] [Abstract][Full Text] [Related]
14. Focus on paroxetine.
Green B
Curr Med Res Opin; 2003; 19(1):13-21. PubMed ID: 12661775
[TBL] [Abstract][Full Text] [Related]
15. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study.
Fabian TJ; Amico JA; Kroboth PD; Mulsant BH; Corey SE; Begley AE; Bensasi SG; Weber E; Dew MA; Reynolds CF; Pollock BG
Arch Intern Med; 2004 Feb; 164(3):327-32. PubMed ID: 14769630
[TBL] [Abstract][Full Text] [Related]
16. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
[TBL] [Abstract][Full Text] [Related]
17. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder.
Appelhof BC; Brouwer JP; van Dyck R; Fliers E; Hoogendijk WJ; Huyser J; Schene AH; Tijssen JG; Wiersinga WM
J Clin Endocrinol Metab; 2004 Dec; 89(12):6271-6. PubMed ID: 15579788
[TBL] [Abstract][Full Text] [Related]
18. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression.
Reis M; Aberg-Wistedt A; Agren H; Höglund P; Akerblad AC; Bengtsson F
Hum Psychopharmacol; 2004 Jul; 19(5):283-91. PubMed ID: 15252820
[TBL] [Abstract][Full Text] [Related]
19. Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders.
Yasui-Furukori N; Nakagami T; Kaneda A; Inoue Y; Suzuki A; Otani K; Kaneko S
Hum Psychopharmacol; 2011 Dec; 26(8):602-8. PubMed ID: 22102561
[TBL] [Abstract][Full Text] [Related]
20. A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats.
Velez de Mendizabal N; Jackson K; Eastwood B; Swanson S; Bender DM; Lowe S; Bies RR
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):721-33. PubMed ID: 26395999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
